EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks

Fan Zhang, Ming-Hui Chen, Xiuyu Julie Cong, Qingxia Chen

Statistical Modelling · 2021-02 · 21 (1-2) · 30-55

DOI: 10.1177/1471082x20933363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Modelling, online erschienen am 27.07.2020. Verfasst von Fan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., Groton, CT, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Longitudinal biomarkers such as patient-reported outcomes (PROs) and quality of life (QOL) are routinely collected in cancer clinical trials or other studies. Joint modelling of PRO/QOL and survival data can provide a comparative assessment of patient-reported changes in specific symptoms or global measures that correspond to changes in survival. Motivated by a head and neck cancer clinical trial, we develop a class of trajectory-based models for longitudinal and survival data with disease progression. Specifically, we propose a class of mixed effects regression models for longitudinal measures, a cure rate model for the disease progression time ([Formula: see text]) and a Cox proportional hazards model with time-varying covariates for the overall survival time ([Formula: see text]) to account for [Formula: see text] and treatment switching. Under the semi-competing risks framework, the disease progression is the non-terminal event, the occurrence of which is subject to a terminal event of death. The properties of the proposed models are examined in detail. Within the Bayesian paradigm, we derive the decompositions of the deviance information criterion (DIC) and the logarithm of the pseudo-marginal likelihood (LPML) to assess the fit of the longitudinal component of the model and the fit of each survival component, separately. We further develop [Formula: see text]DIC as well as [Formula: see text]LPML to determine the importance and contribution of the longitudinal data to the model fit of the [Formula: see text] and [Formula: see text] data.

Schlagwörter

Stichwörter der Autor:innen

Cure rate modelDIC DecompositionMarkov chain Monte CarloPatient-reported outcomeShared parameter modelTime-varying covariates

Autor:innen und Institutionen

  • Pfizer Inc., Groton, CT, USA.
  • Department of Statistics, University of Connecticut, Storrs, CT, USA.
  • Everest Medicines, Shanghai, China.
  • Department of Biostatistics, Vanderbilt University, Nashville, TN, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Zhang, F., Chen, M. H., Cong, X. J., & Chen, Q. (2021). Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks. Statistical Modelling, 21(1-2), 30-55. https://doi.org/10.1177/1471082x20933363

Vancouver

Zhang F, Chen MH, Cong XJ, Chen Q. Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks. Statistical Modelling. 2021;21(1-2):30-55. doi:10.1177/1471082x20933363

BibTeX
@article{Zhang2021,
  author = {Zhang, Fan and Chen, Ming-Hui and Cong, Xiuyu Julie and Chen, Qingxia},
  title = {Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks},
  journal = {Statistical Modelling},
  year = {2021},
  volume = {21},
  number = {1-2},
  pages = {30--55},
  doi = {10.1177/1471082x20933363}
}
Kostenlos starten →